← All organizations
Highest phase reached
Phase 3
First clinical trial
Mar 1, 2006First marketed drug
Mar 17, 2015First NDA
Mar 17, 2015Last known activity
Jul 25, 2025
Timeline
2000s
- Jan 1, 2006
Asklepion— Founded
2010s
- Mar 17, 2015
cholic acid— NDA Organization
Drugs by trial phase (8 distinct, 11 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Lung Injury
- Cardiovascular Diseases
- Congenital Abnormalities
- Endocardial Cushion Defects
- Heart Defects, Congenital
- Heart Diseases
- Heart Failure
- Heart Failure, Diastolic
- Heart Failure, Systolic
- Heart Septal Defects
- Heart Septal Defects, Atrial
- Heart Septal Defects, Ventricular
- Hypertension, Pulmonary
- Lung Injury
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Myocardial Ischemia
- Respiratory Distress Syndrome
- Respiratory Insufficiency
- Wounds and Injuries
Marketed drugs (2)
Recent trials (14)
- NCT06989567Lead sponsorPhase 3Jul 25, 2025
- NCT05598333Lead sponsorPhase 2Dec 31, 2022
- NCT05253209Lead sponsorPhase 3Jun 29, 2022
- NCT05230459Lead sponsorPhase 1/Phase 2May 31, 2022
- NCT04852172Study directorPhase 1/Phase 2Apr 29, 2021
- NCT04852172Lead sponsorPhase 1/Phase 2Apr 29, 2021
- NCT04570384Study directorPhase 2Oct 15, 2020
- NCT04570384Lead sponsorPhase 2Oct 15, 2020
- NCT04179643Lead sponsorPhase 1Nov 20, 2019
- NCT02891837Study directorPhase 3Aug 1, 2016
- NCT02891837Lead sponsorPhase 3Aug 1, 2016
- NCT01120964Lead sponsorPhase 1/Phase 2Sep 1, 2010
- NCT00335244Lead sponsorPhase 3May 1, 2006
- NCT00428935CollaboratorPhase 1Mar 1, 2006
Details
- Founded
- Baltimore, MD, US Jan 1, 2006
- First NDA
- Mar 17, 2015
- Last known activity
- Jul 25, 2025
Designations held
- Orphan drug
- Priority review